Evidence map›Paper›PMID 41694588›Full record

ArticleInternational journal of biological sciences2026

Targeted Induction of Cancer Cell Necroptosis Potentiates Anti-PD-1 Immunotherapy via CD80 Activation.

Xu Zhang, Detian Zhang, Zhe Zhou, Waner Liu, Susi Zhu, Siyu Xiong, Xiang Chen, Cong Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xu ZhangThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Detian ZhangThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Zhe ZhouThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Waner LiuThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Susi ZhuThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Siyu XiongThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Xiang ChenThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Cong PengThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insufficient infiltration or dysfunction of lymphocytes in the tumor immune microenvironment is considered to be a contributing factor to poor immunotherapy outcomes in solid tumors. Necroptosis, a form of immunogenic cell death, has attracted increasing interest because of its unique role in regulating tumor immune responses. CL-387785, a third-generation EGFR inhibitor, has been reported to inhibit tumors by regulating the cell cycle and inducing apoptosis; however, the underlying mechanisms remain unclear. In this study, we demonstrated that CL-387785 effectively suppressed the malignant phenotype of melanoma and lung cancer and confirmed that cancer cells undergo necroptosis, as evidenced by morphological and protein-level analyses. Further in vivo and in vitro experiments revealed that CL-387785 enhances tumor cell killing by immune cells by inducing CD80 expression on the tumor cell surface, thereby increasing CD8

Indexed as

B7-1 AntigenImmunotherapyNecroptosisAnimalsApoptosisCell Line, TumorHumansMelanomaMiceNF-kappa BReceptor-Interacting Protein Serine-Threonine KinasesSignal TransductionB7-1 AntigenNF-kappa BReceptor-Interacting Protein Serine-Threonine KinasesCD80immunotherapynecroptosisTRADDtumor immune microenvironment

Identifiers

PMID41694588
PMCPMC12905644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.